Krishnaswamy Yeleswaram Sells 2,840 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) insider Krishnaswamy Yeleswaram sold 2,840 shares of the company’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $30.05, for a total value of $85,342.00. Following the completion of the transaction, the insider owned 296,991 shares of the company’s stock, valued at $8,924,579.55. The trade was a 0.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Rapport Therapeutics Price Performance

Shares of Rapport Therapeutics stock opened at $27.66 on Wednesday. Rapport Therapeutics, Inc. has a 52-week low of $6.43 and a 52-week high of $42.27. The firm has a market capitalization of $1.32 billion, a PE ratio of -10.21 and a beta of 1.63. The company’s fifty day moving average price is $28.23 and its two-hundred day moving average price is $22.43.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.06. Analysts predict that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on RAPP shares. Wall Street Zen upgraded Rapport Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Wednesday, October 8th. HC Wainwright upped their target price on shares of Rapport Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Citizens Jmp lifted their price target on shares of Rapport Therapeutics from $77.00 to $80.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Finally, Truist Financial initiated coverage on shares of Rapport Therapeutics in a research report on Tuesday, September 16th. They issued a “buy” rating and a $44.00 price target on the stock. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RAPP. Russell Investments Group Ltd. bought a new stake in Rapport Therapeutics during the 3rd quarter worth about $43,000. Strs Ohio grew its stake in shares of Rapport Therapeutics by 23.5% during the third quarter. Strs Ohio now owns 2,100 shares of the company’s stock valued at $62,000 after purchasing an additional 400 shares during the last quarter. Corebridge Financial Inc. grew its stake in shares of Rapport Therapeutics by 79.1% during the first quarter. Corebridge Financial Inc. now owns 8,271 shares of the company’s stock valued at $83,000 after purchasing an additional 3,653 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Rapport Therapeutics by 86.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock valued at $99,000 after buying an additional 4,582 shares during the last quarter. Finally, MetLife Investment Management LLC increased its stake in shares of Rapport Therapeutics by 90.2% in the 1st quarter. MetLife Investment Management LLC now owns 10,863 shares of the company’s stock valued at $109,000 after buying an additional 5,153 shares during the period.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.